Furthermore, in SSc patients, increased serum RANKL levels have been observed (125), and TRIAL, a ligand of OPG with vascular protection properties (126), was found to be higher in SSc compared to the general population, suggesting a possible link between microvascular damage and bone loss. The gene discussed is TNFSF11; the disease is systemic sclerosis.